Anti-cancer pharmaceutical stocks
1, Jiangsu Wuzhong: Holding subsidiary Wuzhong Pharmaceuticals is currently in the research "national class of biological anti-cancer drugs recombinant human vascular endothelial inhibitor injection to obtain the research and development and industrialization of" the project in the application of the third phase of the clinical research phase, with independent intellectual property rights, in 2006, has been the national "863" project support for non-small-cell lung cancer. The project is in the phase III clinical research stage, with independent intellectual property rights, and in 2006, it was supported by the national "863" project for non-small cell lung cancer, and in November 2010, it was awarded the Jiangsu Provincial Science and Technology Achievement
Fruit syrup.
2, Haixin shares: independent research and development of a national class of new drugs, the drug called "antigen-sensitized human dendritic cells (APDC)", can be used for the treatment of rectal cancer, by the Haixin Biotechnology Company (the company's shareholding of 51%) and the Second Military Medical University of Shanghai cooperation in research and development, a national class of new drugs, is China's first independent R & D State Food and Drug Administration (SFDA) formally approved for advanced colorectal cancer APDC therapeutic vaccine, 09 annual report disclosed that the third phase of the clinical has been through the State Drug Administration to organize expert demonstration, the approval is in the process of approval of the enterprise through the efforts of the state "major new drug creation" fund of nearly 5 million yuan.
3, Yatai Group: investment in the pharmaceutical industry -- the company to biological vaccines and anti-tumor series of drugs for the development of new products direction, has formed to "sen one capsule", anti-cancer biological missile for the leading anticancer series of products, but also reserves interleukin-11, ginsenoside, ginsenoside, ginsenoside, ginsenoside, ginsenoside, ginsenoside and other drugs. At the same time, we also have interleukin-11, ginsenoside Rg3 injection and other new anti-cancer drugs under research.
4, Shuanglu Pharmaceuticals: The company was selected as one of the "Beijing Biomedical Industry Leapfrog Development Project" and the first batch of "Ten Hundred Thousand Project" key cultivation enterprises in Zhongguancun National Innovation Demonstration Zone. In the fields of tumor therapy, anti-inflammatory and analgesic, cardiovascular and liver disease, the company has stockpiled a number of advantageous varieties with domestic and international market potential, and strives to launch more than three antibody and vaccine drugs. In the field of liver disease treatment, the company will continue to cultivate heavyweight varieties, and strive to become an important enterprise in the field of liver disease treatment in China. The company's main varieties of recombinant human granulocyte colony-stimulating factor, interleukin-11, menthyl aminotransferase, anti-tumor products and other more than 10 varieties are entering the market in Eastern Europe, Asia, South America.
5, Sihuan Biological: the company's main products include a new class of anti-cancer drugs for injection of recombinant human interleukin-2 (for renal cancer, malignant melanoma and other malignant tumors comprehensive treatment), recombinant human interleukin-2 injection, recombinant human granulocyte stimulating factor injection, recombinant human erythropoietin injection, which injection of recombinant human interleukin-2 is a national program Recombinant human interleukin-2 for injection is an industrialized gene engineering product under the national project "Development, pilot production and clinical application of genetically engineered human interleukin-2"; Beijing Sihuan Biopharmaceutical, in which 55% of the shares are still held, is the earliest enterprise engaged in research and production of genetically engineered pharmaceuticals and diagnostic reagents in China, and its proprietary technologies include interleukin-2 (used in the treatment of liver cancer), interferon, EPO, G-CSF, and G-CSF, EPO, G-CSF and other sublingual tablets.
6, Double Crane Pharmaceuticals: the company's main business for oncology, cardiovascular and cerebrovascular diseases, hepatitis, organ transplantation in the field of genetic engineering drugs, chemical, biochemical drug development and production.
7, Anke biology: the company intends to introduce anti-tumor drug tigio tablet project, tigio is a compound anti-tumor new drug, mainly used for the treatment of advanced or metastatic gastric cancer, is expected to put into production in 2012, the annual production capacity of 30 million tablets.
8. Fengyuan Pharmaceutical: Fengyuan Zhongren Pharmaceutical, a joint venture between the company and Zhongren Science and Technology (in which the company holds a 60% stake), guarantees that the new anti-cancer drug of cisplatin implant will be listed by the end of September 2012; the company has vigorously invested in the research and development of new drugs for adjuvant treatment of cancer.
9, Puluo shares: the company holds 98.07% of Zhejiang Puluo Kangyu Pharmaceuticals production of Baxin is the national second class of new antitumor drugs; the company declared in the first half of 2010, "genetic engineering enzyme synthesis of D-p-hydroxyphenylglycine Deng potassium salt of high-tech industrialization demonstration project" was included in the national high-tech industrialization demonstration project. Demonstration Project of High-tech Industrialization of D-p-hydroxyphenylglycine --Hengdian system"
10, Southwest Synthesis: the company and the Founder Institute of Pharmaceutical Research cooperation of Compradine disodium phosphate (CA4P) and injection is a vascular targeting drugs or endothelial disruption of the drug, the mechanism is to cause the tumor blood supply is rapidly interrupted resulting in the tumor due to insufficient oxygen supply. The mechanism is to cause rapid interruption of tumor blood flow supply leading to tumor death due to insufficient oxygen supply and nutritional starvation, and it takes about 5-6 years for the production approval of this drug. -- "Taiji"
11. Taiji Group: The company owns new anti-cancer drugs with independent intellectual property rights, and is striving to complete the declaration of clinical approvals by the end of 2010. Jointly developed 4 new drugs with independent intellectual property rights with scientific research institutes: new preparation of anti-cancer drug, new drug for diabetes (complications) and 2 new cardiovascular drugs, of which 2 have been granted clinical approvals and 1 is declaring for production approvals, and independently screened 901, 902, 903, 904, 905 new product projects. 2009 scientific and technological innovation work has laid a solid foundation for building an innovative enterprise.
12, Fosun Pharmaceuticals: the company's 74% stake in Shanghai Fuhong Hanlin biotechnology is committed to the research and development of large molecules of monoclonal antibody drugs and industrialization; the company and the international pharmaceutical companies Chemo Group in Shanghai Chemo biomedical platform for the construction of the monoclonal antibody drug project will be the introduction of four treatment of tumors and wind-like off monoclonal antibody drugs. -- "Renaissance Department"
13, Hai Zheng Pharmaceutical: the company is China's leading manufacturer of APIs, is one of China's largest production base of antibiotics, anti-tumor drugs.
14, Hengrui Medicine: the company's single enantiomer of the chiral drug-calcium levofolinate can be used to enhance the antitumor activity of 5-fluorouracil, mainly for the treatment of osteosarcoma after high-dose methotrexate treatment and folic acid antagonism related to the symptoms and colon cancer, renal cancer; the company's a variety of antitumor drugs ranked first in the country, of which three products for the domestic exclusive production, the company's many antitumor drugs. Existing generic drugs oxaliplatin and docetaxel are in the growth period, and irinotecan is also entering the rapid growth period; the company is to have molecularly targeted antitumor drugs apatinib mesylate.
15, China's new pharmaceutical: the company's 40% stake in the Hualida bio-engineering to take the lead in genetic engineering pharmaceutical technology dedicated to anti-virus, anti-tumor drug research and development and industrialization, with the leading product "Anfolon" - the second generation of genetically engineered α-2b interferon.
16, Hainan Haiyao Pharmaceuticals: the company's main products include anti-tumor drug Paclitaxel injection, which can be used for the treatment of ovarian, breast, lung and nasopharyngeal cancers.
17, China Resources Sanjiu: the company's 83.68% stake in Anhui Jinchan Biochemical mainly produces anticancer drugs Huachunin injection, which can be used for the treatment of middle and late-stage tumors, chronic hepatitis B and other diseases. -- "China Resources"
18, goodwill pharmaceutical: the company produces anti-tumor drug gemcitabine hydrochloride is mainly used for the treatment of pancreatic cancer and non-small cell lung cancer (at present, only the United States Eli Lilly, Jiangsu Haosen and goodwill Pharmaceuticals, three factories to produce this (Currently, only three pharmaceutical companies in China, namely Eli Lilly and Jiangsu Haosen, produce this drug).
19, Lemay Pharmaceuticals: the company's core technologies are lymphatic targeted therapy nanomedicine technology, drug micro-nanometer dispersion and suspension preparation technology and sterile API preparation technology.
20, Renfu medicine: the company holds 81.07% stake in Hubei Gedian Renfu Pharmaceuticals is a professional engaged in steroid hormone APIs, fertility regulating drugs and antitumor drug R & D and production enterprises; the company holds a 52% stake in the Shenzhen Xinpeng bio-engineering is the development of international leading anti-cancer gene drug project TR-1 drugs, is expected to obtain the certificate of the first class of new drugs in 3-5 years.
21, ST Changxin: the company holds 51% of Changan International Pharmaceuticals has the world's latest third-generation platinum anti-tumor drug Lopressor in China's exclusive production and operation of the patent.
22, Jilin Aodong: the company's controlling subsidiary Yanji Pharmaceuticals has the "injection of compound pancreatic ribonucleic acid preparation method" patent is based on bovine pancreas as raw material, with anti-cancer, anti-aging, enhance immunity function, reduce radiation, chemotherapy toxic side effects, so that the cancer cells caused by the vacuolated degeneration of cancer cells, cancer cell lysis.
23. Huashen Group: The company owns the primary liver cancer drug iodine [131I] Metuximab Injection (Ricardin), which is a national first-class innovative drug and the world's first gene drug using monoclonal antibody targeted therapy for liver cancer, and the company has its own intellectual property rights to use it in the treatment of middle- and late-stage liver cancer.
24, Guilin Sankin: The company's research and development projects include the field of cancer treatment.
25, Yabao Pharmaceuticals: the company is researching and developing new innovative anti-cancer drugs.
26, tianshili: the company and France's TRANSGENE formed tianshili Genesis Jie (tianjin) biopharmaceutical will be committed to transgenic technology for cancer and infectious diseases gene immunotherapy.
27, Yibai Pharmaceuticals: the company has gene technology of anti-tumor traditional Chinese medicine Aidi injection products, in addition to the purchase of genetic engineering methods can be used to obtain polypeptide chain products VEGI proprietary technology, can be directly activated by different types of immune cells in order to inhibit or eliminate cancer cells.
28, Haiwang biological: the company formed to anti-tumor products and biological products as the leading, covering cardio-cerebral vascular, respiratory system, digestive system, such as 11 categories of varieties of complete product system.
29, Lansheng shares: the company participated in 34.65% Lansheng Guojian Pharmaceuticals and CITIC Pacific *** with the investment in the establishment of "Shanghai CITIC Guojian Pharmaceuticals Company Limited", Lansheng Guojian accounted for 41.69%, the company accounted for 0.73%. 08 years CITIC Guojian development of biological new drugs In 2008, CITIC Guojian developed a new biological drug "Yisepu" (recombinant human 11 tumor necrosis factor receptor-antibody fusion protein for injection), which won the second prize of National Science and Technology Invention Award, and it is the first humanized monoclonal antibody drug that has been industrialized and marketed in China.
30, Fudan Fuhua: the production of flutamide tablets, a new drug for the treatment of prostate cancer.
First generic series:1, Hengrui Medicine: oxaliplatin, docetaxel, irinotecan;
2, Envar Pharmaceuticals: ziprasidone, the original manufacturer of Pfizer;
3, Baiyunshan: Fotile (imitation of Tamiflu);
4, Hainan Haiyao Pharmaceuticals: Paclitaxel injection, cefoxitin sodium;
5, Xinliyi Taitai: Taijia (clopidogrel hydrogencarbazone);
5, Xinliyi Taitai: Taijia (clopidogrel bisulfate) Gray);
6, Shanghai Pharmaceuticals: generic Tamiflu;
7, Haizheng Pharmaceuticals: Tamiflu intermediates;
8, Tongrentang: three generic varieties have entered the approval and production process;
9, Shuanghe Pharmaceuticals: March 27, 2009 officially launched the company's latest generic drug development results- "Crown Sharp Generic Name: Pivacalcium";
10, Changchun High-Tech: Exenatide products in the country's first through the State Food and Drug Administration's approval of the drug, the drug is listed by international diabetes experts as the first of the four major potential medicines;
11, Kangzhi Pharmaceuticals: Ruizhiqing (Nimesulide granules).
Exclusive Chinese medicine series:
1, Yunnan Baiyao: Baiyao series, top-secret formula of the state, and the protected varieties of the first national class of Chinese medicines;
2, Pientzehuang: Pientzehuang series, top-secret formula of the state, and the protected varieties of the first national class of Chinese medicines;
3, Wohua Pharmaceuticals: Heart Kesu tablets, and protected varieties of the national traditional Chinese medicines;
4, Dong'a Colla Corii Asini: Colla Corii Asini series, the first national list of extended items of intangible cultural heritage;
5. Essence Pharmaceuticals: Wang's Baochi Pills and Ji Desheng Snake Tablets, national confidential varieties of traditional Chinese medicines;
6. Zhongheng Group: Thrombotoxic Injection;
7. Qianjin Pharmaceuticals: gynecological Qianjin Tablets;
8. Zhongxin Pharmaceuticals: Quick-acting Heart-Saving Pills, national confidential varieties of traditional Chinese medicines;
9, Guangzhou Pharmaceuticals: thirst-quenching pills;
10, Ma Yinglong: musk hemorrhoid cream;
11, Duiyiwei: Duiyiwei series;
12, Jinling Pharmaceuticals: pulsatilla Ning injection;
13, Tiansheli: compound danshen drip pill;
14, China Resources Sanjiu: 999 cold and flu Ling, diyanping, Zhengtianwan Gastrointestinal, Hua toad injection, the national confidentiality of the distribution;
15, Jiuzhitang: donkey gum blood tonic punch, hepatitis B Ning punch, the state's second-grade protected varieties of traditional Chinese medicine. Chidan Huangxiao Granules, a national confidential formula;
16, Tongrentang: Liuwei Di Huang Pills;
17, Taiji Group: Syrup of Emergency Support;
18, Tongjunge: Gui Zhi Combination, Sijunzi Combination, Exorcising Worms and Eliminating Food Tablets, a national protected variety of traditional Chinese medicine;
19, Hainan Haiyao Medicine: Fengtate Gastrointestinal Kang Granules, a national protected variety of traditional Chinese medicine;
20, Jiaying Pharmaceutical: double material throat wind dispersal;
21, Guilin Sankin: Sankin tablets, watermelon cream series;
22, Qizheng Tibetan medicine: Qizheng pain relief paste cream, the national traditional Chinese medicine protected varieties, the state secret varieties;
23, Tibet Pharmaceuticals: Nodikang series;
24, Antelope Pharmaceuticals: Tongluo to remove the pain of the cream, the strong bones of the Musk Pain Relieving Cream
25, Meiluo Pharmaceuticals: injury bone-setting tablets, ichthyosis tablets, Zhuper Anshen Dan, the national traditional Chinese medicine protection varieties;
26, Yabao Pharmaceuticals: Dinggui umbilical cord sticker;
27, Kang Yuan Pharmaceuticals: hot toxin Ning injection, pain in the injection;
28, KANG Enbai: Kodaling, the national traditional Chinese medicine protection of the exclusive varieties. Wuling capsule, the national Chinese medicine protection varieties;
29, Jiangzhong Pharmaceuticals: compound grass coral tablets, Jiangzhong brand gastric elimination tablets;
30, Shanghai Furen: Yixin Tongxin particles, tooth pain and anti-inflammatory spirit particles;
31, Sanjing Pharmaceuticals: Shuanghuanglian series;
32, Wuhan Healthy People: Longmu Zhuangbao particles, the first national level of protection of Chinese medicine varieties;
32, Wuhan Healthy People: Longmu Zhuangbao particles, the first national level of protection of Chinese medicine Zixin Pharmaceuticals: Kidney tonifying and tranquillizing oral solution, four-miao pills;
34 Beilu Pharmaceuticals: Nine flavors of Zhenxin granules;
35 Hongri Pharmaceuticals: Haibizheng injection, a state-kept secret formula;
36 Yibai Pharmaceuticals: AiDi injection, a state-kept secret formula;
37 Furey Co. Soft liver tablets, the world's first professional treatment of liver fibrosis drugs;
38, Hansen Pharmaceuticals: four mill soup;
39, Taiantang: anti-inflammatory jock itch wet cream, cardiac pills, unicorn pills;
Exclusive Vaccine Series:1, Tiantan Biological: MMR triple vaccine for the first time in the country;
2, Changchun High-tech: chickenpox, anti-AIDS vaccines;
3, Yueyang Xingchang: gastric disease vaccine;
4, Chongqing Beer: hepatitis B vaccine;
5, Watson Biological: meningitis, pneumonia and other vaccines;
6, Lixiang Pharmaceuticals: pneumonia, chickenpox, hepatitis A and B vaccine;
7, Zhifei Biological: meningitis, Vicenza;
8, Kewa Biological: the company's production of hepatitis B virus, Hepatitis C virus, human immunodeficiency virus (Ι) nucleic acid detection kit (PCR-fluorescence method) to obtain the Drug Administration new drug certificate and production approval number.
Europe and the United States pass series:1, Jingxin Pharmaceuticals: simvastatin API;
2, Enhua Pharmaceuticals: following the February 2, 2009 gabapentin API received EU GMP certification, the company's ziprasidone mesylate raw materials and injections on February 5, the SFDA issued a new drug certificate and production approval;
3, Haixiang Pharmaceuticals: the only domestic manufacturer of biphenyl dibenzoate, and also the only manufacturer of biphenyl dibenzoate. Production of biphenyl dibenzoate manufacturers, but also to enter the international BIT products market is the only Chinese company;
4, modern pharmaceuticals: anti-AIDS drugs will be certified by the FDA; the largest domestic production of lipoic acid API, 90% of the products are exported to Japan and Europe. The only domestic enterprise mastering the chiral splitting technology of lipoic acid, which can produce high-end products with low residual lipoic acid;
5. Southwest Synthesis: all the products have passed the GMP certification, of which 9 products are registered in the U.S. FDA, 4 products have passed the FDA certification, and 5 products have obtained the COS certificate in Europe;
6. Fosun Pharmaceuticals: Artesunate tablets have passed the WHO's GMP review, for the WHO global third direct supplier of antimalarial drugs, completely open the company's internationalization road. 2008, the export of artemisinin antimalarial drugs to continue to maintain the first;
7, Huadong Pharmaceuticals: the leading product cyclosporine raw materials through the European Union Committee for the Quality of Medicines COS certification, the validity of the period of 5 years;
8, Haizheng Pharmaceuticals: at the end of 08 has the At the end of 2008, the number of FDA and EU COS certificates reached 18 and 15, and there are more than 20 products are being declared;
9, Zhongxin Pharmaceutical: quick-acting heart pill formula is classified as a state-secret formula, Shu Brainxin Drops is the first treatment of cerebrovascular diseases of traditional Chinese medicine drops preparation, the first to enter the European Union of the traditional Chinese medicine products, Huo Xiang Zhengqi soft capsule, the first Chinese pCms in soft capsules dosage;
10, Huazhong Pharmaceutical: the main product cyclosporine raw materials through the EU Drug Quality Management Committee COS certification. p>
10, Huahai Pharmaceuticals: has become the domestic anti-AIDS drugs HAART treatment program (cocktail therapy) required by the protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors of the three major series of products have been approved by the national production of the only enterprise.
11, Tianshili: January 20, 2010, the main product compound danshen drip pill FDA (U.S. Food and Drug Administration) Phase II clinical trials have been completed. The phase II clinical trial study to determine the efficacy and dose response of compound danshen drip pill for patients with chronic stable angina pectoris in the U.S. On August 9, 2010, the U.S. phase III clinical trial was approved;
12, Zhejiang Pharmaceuticals: January 6, 2010, received a written notice from the U.S. FDA, the company's subsidiary of the Xinchang Pharmaceutical Factory production of APIs Benfluorexol and Artemether on-site inspection reports Has been formally approved by the U.S. FDA, allowing access to the U.S. market sales;
13, Changchun High-tech: growth hormone aqueous, long-acting growth hormone and oral growth hormone, to become the world's leading growth hormone production and sales company; growth hormone will be demonstrated through the FDA;
14, Hengrui Medicine: Regliflozin successfully entered the U.S. phase I clinical trial stage;
15, Hepro: the world's largest production and marketing scale, but also China's only at the same time to obtain the U.S. FDA certification and the European Union CEP certification of heparin sodium API manufacturers;
16, Purol Pharmaceuticals: oxfloxacin products to obtain the European Pharmacopoeia Committee issued by the COS certificate, so that Kangyu Pharmaceuticals became the world's few companies to obtain the COS certificate of the product, the company The project of "development of immobilized D-hydantoinase and D-carbamoyl hydrolase" has been listed in the National 863 Plan Project
Exclusive gene series:1. Tibet Pharmaceuticals: Freeze-drying recombinant human cerebral natriuretic peptide, also known as new vivaxin, is a gene drug for the treatment of heart failure, which is only researched in China and the United States up to now. Only China and the United States;
2, Tonghua Dongbao: recombinant human insulin;
3, Yibai Pharmaceuticals: soluble vascular endothelial growth inhibitory factor (VEGI);
4, Tianmu Pharmaceuticals: lyophilized murine epidermal growth factor;
5, Haizheng Pharmaceuticals: the first gene drug tumor necrosis factor receptor antibody fusion protein into the Phase II Zhongxin Pharmaceutical: the world's first "pre-filled" recombinant human interferon α-2b injection, Anfranilone, and the world's first recombinant human interferon α-2b spray, Jiefu, which have filled the domestic market. --Jiefu, filling the domestic blank;
7, Changchun High-Tech: growth hormone aqueous, long-acting growth hormone and oral growth hormone, to become the world's leading growth hormone production and sales company; growth hormone will be demonstrated by the FDA;
8, Ancor Biologicals: the only one to produce interferon at the same time, Growth Hormone;
9, Daan gene: the company is a molecular diagnostic technology as the leading set of clinical testing reagents and instruments, research and development, production, sales and the national chain of independent medical laboratory clinical testing services as one of the biomedical high-tech enterprises.
Pharmaceutical business series:1, Nanjing Pharmaceutical: the country's fourth largest pharmaceutical distribution enterprises;
2, the first medicine: Shanghai's second largest pharmaceutical distribution enterprises;
3, Sinopharm: the company is the State Drug Administration to determine the 41 drugs in the country's cross-provincial retail chain of pilot enterprises, one of the eight drug e-commerce pilot enterprises. The controlling shareholder is Sinopharm Holdings (HK1099);
4, Fosun Pharmaceuticals: 34.66% participation in Sinopharm Holdings (HK1099) to maintain the No. 1 position in China's drug distribution;
5, China's pharmaceuticals: the General Meikang in the national pharmaceutical and health care industry import and export volume ranked No. 1 in the Chinese enterprises, the whole industry ranked No. 3;
6, Tongrentang Tongrentang has nearly 500 "Beijing Tongrentang stores" and nearly 1,000 image counters; the group has also opened 20 branches in 13 countries and regions around the world;
7, consistent pharmaceuticals: holding 100% of the equity of Sinopharm Holding Guangzhou, Sinopharm Guangzhou is the core enterprise of Sinopharm Holding in southern China, with more than 800 pharmaceutical commercial distribution network, covering the whole industry;
7, unanimous pharmaceuticals: holding 100% equity of Sinopharm Holding Guangzhou, Sinopharm Guangzhou is the core enterprise of Sinopharm Holding in south China. More than pharmaceutical commercial distribution network, covering the country's 29 provinces, cities and districts of large and medium-sized cities;
8, Jiasitang: Beijing's largest pharmaceutical business;
9, Jiuzhoutong: the third national pharmaceutical business, the first private pharmaceutical business;
10, the Intec Group: wholesale of pharmaceuticals and medical equipment;
11, Zhejiang Zhenyuan: pharmaceuticals and medical equipment
12, ha pharmaceutical shares: "national brand general medicine enterprise + regional commercial leader", industry position and scale advantage is outstanding company industry and commerce as a whole one of the five roses of the regional leader: industry chain covers six pharmaceutical industry field, is a national brand general medicine company; pharmaceutical commercial network is perfect: has more than 1,000 Chain drugstores, pure sales, wholesale and retail business accounted for about 80%, 66%, 76% of the share of Harbin City, respectively, is the only commercial company with province-wide coverage, and is expected to further expand in the northeast.
Hospital chain series:1, Tongze medical: dental hospital chain;
2, Ma Yinglong: anal and intestinal hospital chain;
3, Ai Er Ophthalmology: eye hospital chain.
Infusion series:
1, Shuanghe Pharmaceuticals
2, Kelun Pharmaceuticals
3, Huaren Pharmaceuticals
4, Tonghua Dongbao
Medical equipment series:
1, Wandong Medical: medical X-ray machine the first in the country, CRH is the controlling shareholder;
2, Xinhua Medical: cleaning Sterilizer to fill the gaps in the country, Zimmer Group is the controlling shareholder;
3, Yuyue Medical: stethoscope, blood pressure monitor, oxygen concentrator, wheelchair car;
4, Lepu Medical: intravascular drug-eluting stent system;
5, Yangpu Medical: the third generation of vacuum blood collection system;
6, Xinlitai: high-end medical equipment;
7, Hainan Haiyao: cochlear implants;
8. Jiu'an Medical: electronic blood pressure monitors, blood glucose meters, low-frequency therapeutic instrument.
Vitamin series:1, Northeast Pharmaceuticals: vitamin C, one of the "five families", is one of the country's four leading vitamin C enterprises;
2, North China Pharmaceutical: one of the largest cephalosporin manufacturers and take into account the manufacture of vitamin C and a variety of other medicines;
3, Guangji Pharmaceuticals: company Through revolutionary technological change, overcame the use of rice instead of molasses production of vitamin B2 problems, production efficiency has increased significantly, the cost of a substantial reduction in production output of more than 2,000 tons, the leading product riboflavin;
4, Xinhecheng: the company is a high-tech, high-growth, high efficiency and benefit of the state's key high-tech enterprises, mainly engaged in the production and sale of drugs, health products, pharmaceutical raw materials, pharmaceutical production and sales, the company's intermediate trimethylenephosphonate, vitamin E, vitamin C, vitamin C and other drugs. The company's vitamin E intermediate trimethylhydroquinone and isophytol production ranks first in the country. The leading products are vitamin E.
Bio-chemical pharmaceutical series:
1. Feng Yuan Pharmaceuticals: biological drugs, traditional Chinese medicines, chemically synthesized drugs and their preparations and feed additives;
2. Haiwang Biologicals: biologics, biochemicals, marine medicines, marine biologics, and proprietary Chinese medicines;
3. Lizhu Group: bio-engineered medicines, chemically synthesized APIs, antibiotics, etc.;
4. Sihuan Biologicals: the leading product recombinant human interleukin-2 injection is a national class I biological product;
5. Huashen Group: the production and sale of bioengineered products, the leading product Panax notoginseng Tongshu Capsules, Panax notoginseng Triol Saponin exclusive production and sale. Holding subsidiary of Chengdu Huashen biotechnology limited liability company "oxidized low-density lipoprotein quantitative determination kit, the treatment of intermediate and advanced primary liver cancer multi-center phase IV clinical trial summary report", is the first monoclonal antibody radioimmunotargeting drugs for primary hepatocellular carcinoma treatment;
6, Chengzhi shares: Life sciences, bioengineering, traditional Chinese medicine pharmaceuticals, information technology, fine chemicals;
7, Xiangxue Pharmaceutical: antiviral oral solution, Banlangen granules;
8, Fu'an Pharmaceuticals: engaged in the research and development of antibiotic raw materials and preparations, production and sales, the main products of aminotrenan APIs and formulations, ticarcillin sodium, sulfobenzylcarbamoyl sulfonylcyclohexirine sodium APIs, cefsulosporan sulfamidomethoxime sodium preparations, of which aminotrenan APIs and formulations. Amitranam API and preparations for the company's leading products;
9, Hanyu Pharmaceuticals: R & D, production and sales of chemically synthesized peptide drugs, the main products of peptide pharmaceutical preparations, peptide APIs and customer peptides (customized services) three series;
10, Star Lake Technology: the production and sale of chemical APIs, nucleoside (acid) and amino acid biochemical products, the controlling subsidiary of the Anzai Ltd. implements freeze-dried human rabies vaccine (chicken embryo cells)
11, Hualan Bio: the company is engaged in the research and development of blood products and production of national key high-tech enterprises, and in 1998, the first to pass the GMP certification of the blood products industry for the state designated large-scale biological products manufacturer, in the country in the industry in a leading position among enterprises.
12, Kewa Bio: the company is the largest production volume, the highest market share, the most complete varieties, the largest batch of in vitro diagnostic reagent manufacturers
13, Shutaishen: the company independently developed a class of new drugs - injection of murine nerve growth factor "Sutaishen" and the only national new drug with two types of bowel cleansing and constipation, "Sutaisheng". The company has independently developed a new class of national drugs - the injection of rat nerve growth factor "Sutisan" and domestic only with two indications of intestinal cleansing and constipation constipation drugs - polyethylene glycol electrolyte dispersal agent "Shutaiqing".